Symbols / CASI $0.21
CASI Chart
About
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.21M |
| Enterprise Value | 19.16M | Income | -49.38M | Sales | 26.85M |
| Book/sh | -1.39 | Cash/sh | 0.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 233 | IPO | Jun 12, 1996 |
| P/E | — | Forward P/E | -0.10 | PEG | — |
| P/S | 0.12 | P/B | — | P/C | — |
| EV/EBITDA | -0.45 | EV/Sales | 0.71 | Quick Ratio | 0.18 |
| Current Ratio | 0.30 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.02 | EPS next Y | -2.13 | EPS Growth | — |
| Revenue Growth | -60.50% | Earnings | 2025-11-14 16:00 | ROA | -61.80% |
| ROE | — | ROIC | — | Gross Margin | 35.80% |
| Oper. Margin | -3.33% | Profit Margin | -183.96% | Shs Outstand | 15.49M |
| Shs Float | 9.31M | Short Float | 0.54% | Short Ratio | 2.44 |
| Short Interest | — | 52W High | 3.09 | 52W Low | 0.21 |
| Beta | 0.89 | Avg Volume | 55.60K | Volume | 6.83M |
| Target Price | $4.00 | Recom | None | Prev Close | $0.00 |
| Price | $0.21 | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.21
Latest analyst target
3. DCF / Fair value
$4.00
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$0.21
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-09 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-11-15 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- CASI loses Nasdaq listing, pursues OTC trading after panel ruling - Stock Titan Wed, 25 Feb 2026 08
- CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT - GuruFocus Fri, 27 Feb 2026 05
- CASI Pharmaceuticals stock plunges on Nasdaq delisting notice - Investing.com Wed, 25 Feb 2026 08
- Market Movers | Winners: XWEL, LRMR, CDIO | Losers: NUCL, CASI, KTWO - Trefis Wed, 25 Feb 2026 08
- What Drove CASI Pharmaceuticals' 24% Rise After Hours? - Finviz hu, 26 Feb 2026 08
- Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st ue, 25 Nov 2025 08
- CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network hu, 27 Nov 2025 16
- CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - ACCESS Newswire Wed, 25 Feb 2026 14
- CASI Pharmaceuticals to Be Delisted from Nasdaq - Intellectia AI hu, 26 Feb 2026 11
- Potential buyer offers 30% premium as CASI blood disorder drug shows promise - Stock Titan Mon, 12 Jan 2026 08
- CASI Pharmaceuticals stock surges after Nasdaq grants listing extension - Investing.com ue, 23 Dec 2025 08
- CASI Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Wed, 24 Dec 2025 08
- One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates - simplywall.st ue, 09 Sep 2025 07
- CASI Pharmaceuticals gets extra time to stay on Nasdaq - Stock Titan ue, 23 Dec 2025 08
- Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan ue, 03 Mar 2026 14
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -7.36K | -4.11M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.25 | 0.00 |
| NormalizedEBITDA | -36.15M | -20.15M | -18.51M | -31.90M |
| TotalUnusualItems | 1.29M | -2.39M | -16.44M | -1.50M |
| TotalUnusualItemsExcludingGoodwill | 1.29M | -2.39M | -16.44M | -1.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -39.26M | -26.94M | -41.01M | -36.65M |
| ReconciledDepreciation | 2.33M | 3.74M | 2.42M | 1.81M |
| ReconciledCostOfRevenue | 17.39M | 13.83M | 15.83M | 12.56M |
| EBITDA | -34.87M | -22.54M | -34.95M | -33.40M |
| EBIT | -37.20M | -26.28M | -37.37M | -35.22M |
| NetInterestIncome | -332.00K | 614.00K | 127.00K | 321.00K |
| InterestExpense | 871.00K | 15.00K | 62.00K | |
| InterestIncome | 539.00K | 629.00K | 189.00K | 321.00K |
| NormalizedIncome | -40.55M | -24.56M | -28.69M | -35.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -39.26M | -26.94M | -41.01M | -36.65M |
| TotalExpenses | 67.75M | 59.16M | 69.60M | 65.39M |
| TotalOperatingIncomeAsReported | -39.62M | -25.08M | -34.03M | -41.52M |
| DilutedAverageShares | 15.34M | 13.36M | 13.65M | 13.61M |
| BasicAverageShares | 15.34M | 13.36M | 13.65M | 13.61M |
| DilutedEPS | -2.56 | -2.02 | -3.01 | -2.69 |
| BasicEPS | -2.56 | -2.02 | -3.01 | -2.69 |
| DilutedNIAvailtoComStockholders | -39.26M | -26.96M | -41.01M | -36.65M |
| NetIncomeCommonStockholders | -39.26M | -26.96M | -41.01M | -36.65M |
| PreferredStockDividends | 22.00K | |||
| NetIncome | -39.26M | -26.94M | -41.01M | -36.65M |
| MinorityInterests | 0.00 | -679.00K | -757.00K | -812.00K |
| NetIncomeIncludingNoncontrollingInterests | -39.26M | -26.26M | -40.26M | -35.84M |
| NetIncomeContinuousOperations | -39.26M | -26.26M | -40.26M | -35.84M |
| EarningsFromEquityInterestNetOfTax | -1.19M | -48.00K | -846.00K | 0.00 |
| TaxProvision | 0.00 | -81.00K | 1.98M | 0.00 |
| PretaxIncome | -38.07M | -26.29M | -37.43M | -35.84M |
| OtherIncomeExpense | 1.48M | -1.63M | -11.07M | -946.00K |
| OtherNonOperatingIncomeExpenses | 188.00K | 764.00K | 44.00K | 558.00K |
| SpecialIncomeCharges | -217.00K | -2.01M | -10.78M | -7.49M |
| GainOnSaleOfPPE | 479.00K | 0.00 | -2.06M | -65.00K |
| OtherSpecialCharges | 6.55M | |||
| WriteOff | 0.00 | 2.01M | 0.00 | 865.00K |
| ImpairmentOfCapitalAssets | 696.00K | 0.00 | 8.72M | 0.00 |
| RestructuringAndMergernAcquisition | 6.55M | |||
| EarningsFromEquityInterest | 0.00 | 0.00 | 5.33M | 0.00 |
| GainOnSaleOfSecurity | 1.50M | -381.00K | -5.65M | 5.98M |
| NetNonOperatingInterestIncomeExpense | -332.00K | 614.00K | 127.00K | 321.00K |
| InterestExpenseNonOperating | 871.00K | 15.00K | 62.00K | |
| InterestIncomeNonOperating | 539.00K | 629.00K | 189.00K | 321.00K |
| OperatingIncome | -39.21M | -25.28M | -26.49M | -35.22M |
| OperatingExpense | 50.36M | 45.33M | 53.77M | 52.83M |
| OtherOperatingExpenses | -2.00K | -6.37M | ||
| ResearchAndDevelopment | 8.92M | 9.86M | 16.00M | 14.42M |
| SellingGeneralAndAdministration | 41.44M | 41.84M | 37.77M | 38.41M |
| SellingAndMarketingExpense | 17.87M | 16.45M | 14.33M | 14.71M |
| GeneralAndAdministrativeExpense | 23.58M | 25.39M | 23.45M | 23.70M |
| OtherGandA | 23.58M | 25.39M | 23.45M | 23.70M |
| GrossProfit | 11.15M | 20.05M | 27.28M | 17.61M |
| CostOfRevenue | 17.39M | 13.83M | 15.83M | 12.56M |
| TotalRevenue | 28.54M | 33.88M | 43.11M | 30.17M |
| OperatingRevenue | 28.54M | 33.88M | 43.05M | 30.02M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 411.95K | 411.95K | 275.83K | 7.95K |
| OrdinarySharesNumber | 15.49M | 13.38M | 13.46M | 13.98M |
| ShareIssued | 15.90M | 13.79M | 13.73M | 13.99M |
| NetDebt | 4.92M | 1.81M | ||
| TotalDebt | 22.14M | 21.24M | 1.34M | 2.17M |
| TangibleBookValue | 1.61M | 22.33M | 43.51M | 72.30M |
| InvestedCapital | 20.24M | 43.06M | 44.57M | 84.50M |
| WorkingCapital | 3.12M | 42.62M | 56.42M | 48.78M |
| NetTangibleAssets | 1.61M | 22.33M | 43.51M | 72.30M |
| CapitalLeaseObligations | 3.76M | 2.34M | 1.34M | 2.17M |
| CommonStockEquity | 1.85M | 24.16M | 44.57M | 84.50M |
| TotalCapitalization | 1.85M | 43.06M | 44.57M | 84.50M |
| TotalEquityGrossMinorityInterest | 1.85M | 24.16M | 66.93M | 107.96M |
| MinorityInterest | 0.00 | 22.36M | 23.46M | |
| StockholdersEquity | 1.85M | 24.16M | 44.57M | 84.50M |
| GainsLossesNotAffectingRetainedEarnings | -1.77M | -1.20M | -703.00K | 1.95M |
| OtherEquityAdjustments | -1.77M | -1.20M | -703.00K | 1.95M |
| TreasuryStock | 9.60M | 9.60M | 9.33M | 8.03M |
| RetainedEarnings | -700.08M | -660.82M | -637.16M | -605.64M |
| AdditionalPaidInCapital | 713.30M | 695.78M | 691.77M | 696.22M |
| CapitalStock | 2.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 2.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 51.82M | 51.10M | 29.30M | 30.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.37M | 34.38M | 12.30M | 17.15M |
| OtherNonCurrentLiabilities | 11.82M | 11.82M | 11.82M | 13.22M |
| PreferredSecuritiesOutsideStockEquity | 23.46M | |||
| TradeandOtherPayablesNonCurrent | 1.01M | 2.04M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 2.83M | ||
| NonCurrentDeferredRevenue | 0.00 | 2.83M | ||
| LongTermDebtAndCapitalLeaseObligation | 2.54M | 20.51M | 476.00K | 1.10M |
| LongTermCapitalLeaseObligation | 2.54M | 1.62M | 476.00K | 1.10M |
| LongTermDebt | 18.89M | |||
| CurrentLiabilities | 36.45M | 16.73M | 17.00M | 13.19M |
| OtherCurrentLiabilities | 648.00K | 519.00K | ||
| CurrentDeferredLiabilities | 2.47M | 2.54M | 2.62M | |
| CurrentDeferredRevenue | 2.47M | 2.54M | 2.62M | |
| CurrentDebtAndCapitalLeaseObligation | 19.61M | 728.00K | 868.00K | 1.06M |
| CurrentCapitalLeaseObligation | 1.22M | 728.00K | 868.00K | 1.06M |
| CurrentDebt | 18.39M | |||
| OtherCurrentBorrowings | 18.39M | |||
| LineOfCredit | 0.00 | |||
| PayablesAndAccruedExpenses | 14.37M | 13.46M | 13.52M | 11.61M |
| CurrentAccruedExpenses | 1.33M | 1.12M | 648.00K | 60.00K |
| Payables | 13.04M | 12.34M | 12.87M | 11.55M |
| OtherPayable | 8.47M | 7.15M | 7.53M | 8.67M |
| DividendsPayable | 1.85M | 753.00K | 0.00 | |
| TotalTaxPayable | 481.00K | 2.05M | 652.00K | |
| IncomeTaxPayable | 0.00 | 1.90M | 0.00 | |
| AccountsPayable | 2.72M | 4.44M | 3.29M | 2.22M |
| TotalAssets | 53.67M | 75.27M | 96.23M | 138.30M |
| TotalNonCurrentAssets | 13.90M | 15.92M | 22.81M | 76.33M |
| OtherNonCurrentAssets | 587.00K | 766.00K | 1.06M | 2.18M |
| FinancialAssets | 5.00K | |||
| InvestmentsAndAdvances | 1.72M | 1.68M | 7.46M | 40.13M |
| OtherInvestments | 4.40M | 40.13M | ||
| InvestmentinFinancialAssets | 1.72M | 1.68M | 3.06M | 0.00 |
| AvailableForSaleSecurities | 1.72M | 1.68M | 3.06M | |
| GoodwillAndOtherIntangibleAssets | 238.00K | 1.84M | 1.06M | 12.20M |
| OtherIntangibleAssets | 238.00K | 1.84M | 1.06M | 12.20M |
| NetPPE | 11.36M | 11.63M | 13.23M | 21.82M |
| AccumulatedDepreciation | -5.71M | -4.65M | -2.30M | -2.24M |
| GrossPPE | 17.07M | 16.28M | 15.53M | 24.06M |
| Leases | 7.00M | 7.19M | 7.16M | 1.13M |
| ConstructionInProgress | 0.00 | 23.00K | 5.73M | 12.10M |
| OtherProperties | 3.49M | 2.39M | 1.40M | 9.11M |
| MachineryFurnitureEquipment | 6.58M | 6.68M | 1.24M | 1.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 39.58M | 59.34M | 73.42M | 61.97M |
| OtherCurrentAssets | 2.89M | 2.56M | 2.98M | 1.69M |
| PrepaidAssets | 1.69M | |||
| Inventory | 5.25M | 15.88M | 6.14M | 1.91M |
| FinishedGoods | 5.25M | 15.88M | 6.14M | 1.91M |
| Receivables | 15.35M | 10.14M | 12.97M | 9.80M |
| DuefromRelatedPartiesCurrent | 0.00 | 587.00K | 0.00 | |
| AccountsReceivable | 15.35M | 9.55M | 12.97M | 9.80M |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | 0.00 | ||
| GrossAccountsReceivable | 12.97M | 9.80M | ||
| CashCashEquivalentsAndShortTermInvestments | 16.09M | 30.77M | 51.34M | 48.57M |
| OtherShortTermInvestments | 2.62M | 13.69M | 4.22M | 9.87M |
| CashAndCashEquivalents | 13.47M | 17.08M | 47.11M | 38.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.46M | -22.21M | -26.70M | -42.34M |
| RepurchaseOfCapitalStock | 0.00 | -278.00K | -3.27M | 0.00 |
| RepaymentOfDebt | 0.00 | 0.00 | -4.00M | -1.55M |
| IssuanceOfDebt | 0.00 | 0.00 | 4.00M | 709.00K |
| IssuanceOfCapitalStock | 15.00M | 0.00 | 0.00 | 32.50M |
| CapitalExpenditure | -240.00K | -2.24M | -5.61M | -15.50M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 62.00K | 42.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 1.81M | 0.00 | 0.00 |
| EndCashPosition | 13.47M | 17.08M | 47.11M | 38.70M |
| BeginningCashPosition | 17.08M | 47.11M | 38.70M | 57.06M |
| EffectOfExchangeRateChanges | -1.07M | 518.00K | 1.60M | -469.00K |
| ChangesInCash | -2.55M | -30.55M | 6.80M | -17.89M |
| FinancingCashFlow | 15.43M | -907.00K | -3.27M | 29.64M |
| CashFlowFromContinuingFinancingActivities | 15.43M | -907.00K | -3.27M | 29.64M |
| NetOtherFinancingCharges | -1.68M | -738.00K | -2.02M | |
| ProceedsFromStockOptionExercised | 2.11M | 109.00K | 0.00 | 0.00 |
| NetCommonStockIssuance | 15.00M | -278.00K | -3.27M | 32.50M |
| CommonStockPayments | 0.00 | -278.00K | -3.27M | 0.00 |
| CommonStockIssuance | 15.00M | 0.00 | 0.00 | 32.50M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 0.00 | -839.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | -839.00K |
| ShortTermDebtPayments | 0.00 | 0.00 | -4.00M | -1.55M |
| ShortTermDebtIssuance | 0.00 | 0.00 | 4.00M | 709.00K |
| NetLongTermDebtIssuance | 0.00 | -1.55M | ||
| LongTermDebtPayments | -4.00M | -1.55M | ||
| LongTermDebtIssuance | 4.00M | 0.00 | ||
| InvestingCashFlow | 11.24M | -9.67M | 31.16M | -20.69M |
| CashFlowFromContinuingInvestingActivities | 11.24M | -9.67M | 31.16M | -20.69M |
| NetOtherInvestingChanges | 1.00M | 6.44M | -5.20M | |
| NetInvestmentPurchaseAndSale | 12.35M | -8.43M | -796.00K | 0.00 |
| SaleOfInvestment | 13.76M | 43.32M | 3.73M | 0.00 |
| PurchaseOfInvestment | -1.41M | -51.75M | -4.53M | 0.00 |
| NetBusinessPurchaseAndSale | -1.37M | 0.00 | 30.99M | 0.00 |
| SaleOfBusiness | 0.00 | 0.00 | 33.89M | 0.00 |
| PurchaseOfBusiness | -1.37M | 0.00 | -2.90M | |
| NetIntangiblesPurchaseAndSale | 483.00K | -2.04M | 0.00 | -6.55M |
| SaleOfIntangibles | 500.00K | 0.00 | 0.00 | 0.00 |
| PurchaseOfIntangibles | -17.00K | -2.04M | 0.00 | -6.55M |
| NetPPEPurchaseAndSale | -223.00K | -204.00K | -5.47M | -8.94M |
| SaleOfPPE | 0.00 | 0.00 | 138.00K | 10.00K |
| PurchaseOfPPE | -223.00K | -204.00K | -5.61M | -8.95M |
| OperatingCashFlow | -29.22M | -19.97M | -21.09M | -26.84M |
| CashFlowFromContinuingOperatingActivities | -29.22M | -19.97M | -21.09M | -26.84M |
| ChangeInWorkingCapital | 771.00K | -7.82M | -6.65M | -3.22M |
| ChangeInOtherWorkingCapital | -51.00K | |||
| ChangeInPayablesAndAccruedExpense | -169.00K | -1.61M | 2.13M | 3.79M |
| ChangeInAccruedExpense | 1.55M | -876.00K | -912.00K | 2.30M |
| ChangeInPayable | -1.72M | -739.00K | 3.05M | 1.49M |
| ChangeInAccountPayable | -1.72M | 1.15M | 1.07M | 1.49M |
| ChangeInTaxPayable | 0.00 | -1.89M | 1.98M | 0.00 |
| ChangeInIncomeTaxPayable | 0.00 | -1.89M | 1.98M | 0.00 |
| ChangeInPrepaidAssets | 319.00K | 701.00K | -1.38M | -1.30M |
| ChangeInInventory | 5.83M | -9.74M | -4.23M | -551.00K |
| ChangeInReceivables | -5.21M | 2.83M | -3.17M | -5.16M |
| ChangesInAccountReceivables | -5.79M | 3.42M | -3.17M | -5.16M |
| OtherNonCashItems | 1.19M | 6.55M | ||
| StockBasedCompensation | 1.31M | 7.22M | 7.01M | 7.77M |
| UnrealizedGainLossOnInvestmentSecurities | -1.70M | 581.00K | 8.89M | -5.66M |
| AssetImpairmentCharge | 6.61M | 3.00M | 9.91M | 2.15M |
| DepreciationAmortizationDepletion | 2.33M | 3.74M | 2.42M | 1.81M |
| DepreciationAndAmortization | 2.33M | 3.74M | 2.42M | 1.81M |
| AmortizationCashFlow | 1.06M | 1.29M | 1.21M | 1.35M |
| AmortizationOfIntangibles | 1.06M | 1.29M | 1.21M | 1.35M |
| Depreciation | 1.27M | 2.45M | 1.21M | 468.00K |
| OperatingGainsLosses | 710.00K | -426.00K | -2.42M | -407.00K |
| EarningsLossesFromEquityInvestments | 1.19M | 48.00K | 846.00K | 0.00 |
| GainLossOnInvestmentSecurities | -5.33M | |||
| GainLossOnSaleOfPPE | -479.00K | 0.00 | 2.06M | 65.00K |
| NetIncomeFromContinuingOperations | -39.26M | -26.26M | -40.26M | -35.84M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CASI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|